Status:
COMPLETED
Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children
Lead Sponsor:
Virginia Commonwealth University
Collaborating Sponsors:
University of Louisville
Conditions:
Infection
Renal Dysfunction
Eligibility:
All Genders
Up to 18 years
Brief Summary
The purposes of this study are to identify potential gene and protein markers of aminoglycoside-induced kidney injury in infants, children and adolescents treated with aminoglycoside antibiotics.
Eligibility Criteria
Inclusion
- (1) Hospitalized male and female newborns, infants, children and adolescents (ages birth to 18 years) with a diagnosis of suspected or proven bacterial sepsis, meningitis or other indication necessitating aminoglycoside therapy (2) hospitalized and outpatient newborns, infants, children and adolescents (ages birth to 18 years) who are not receiving aminoglycoside therapy.
Exclusion
- (1) Current treatment with inhaled or ophthalmic aminoglycosides (2) Prior treatment with an aminoglycoside within the last 30 days
Key Trial Info
Start Date :
June 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT00308906
Start Date
June 1 2006
End Date
December 1 2010
Last Update
February 2 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Lousiville
Louisville, Kentucky, United States, 40202
2
Virginia Commonwealth University
Richmond, Virginia, United States, 23298